These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1182 related articles for article (PubMed ID: 28801166)

  • 1. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
    Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
    Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
    Lee S; Abed DA; Beamer LJ; Hu L
    SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
    Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
    Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
    J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
    Pallesen JS; Tran KT; Bach A
    J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
    Pallesen JS; Narayanan D; Tran KT; Solbak SMØ; Marseglia G; Sørensen LME; Høj LJ; Munafò F; Carmona RMC; Garcia AD; Desu HL; Brambilla R; Johansen TN; Popowicz GM; Sattler M; Gajhede M; Bach A
    J Med Chem; 2021 Apr; 64(8):4623-4661. PubMed ID: 33818106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking.
    Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B
    Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington's disease mouse model.
    Moretti D; Tambone S; Cerretani M; Fezzardi P; Missineo A; Sherman LT; Munoz-Sajuan I; Harper S; Dominquez C; Pacifici R; Tomei L; Park L; Bresciani A
    Free Radic Biol Med; 2021 Jan; 162():243-254. PubMed ID: 33096251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.
    Jiang ZY; Lu MC; Xu LL; Yang TT; Xi MY; Xu XL; Guo XK; Zhang XJ; You QD; Sun HP
    J Med Chem; 2014 Mar; 57(6):2736-45. PubMed ID: 24512214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
    Karttunen M; Choy WY; Cino EA
    J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
    Jiang ZY; Lu MC; You QD
    J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
    Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
    Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
    Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
    Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
    Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
    FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
    Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
    J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.
    Richardson BG; Jain AD; Potteti HR; Lazzara PR; David BP; Tamatam CR; Choma E; Skowron K; Dye K; Siddiqui Z; Wang YT; Krunic A; Reddy SP; Moore TW
    J Med Chem; 2018 Sep; 61(17):8029-8047. PubMed ID: 30122040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model.
    Kim S; Indu Viswanath AN; Park JH; Lee HE; Park AY; Choi JW; Kim HJ; Londhe AM; Jang BK; Lee J; Hwang H; Lim SM; Pae AN; Park KD
    Neuropharmacology; 2020 May; 167():107989. PubMed ID: 32032607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery.
    Madden SK; Itzhaki LS
    Biochim Biophys Acta Proteins Proteom; 2020 Jul; 1868(7):140405. PubMed ID: 32120017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
    Lu MC; Shao HL; Liu T; You QD; Jiang ZY
    Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Keap1-kelch inhibitors as potential drug candidates for oxidative stress-orchestrated diseases: A review on In silico perspective.
    Boyenle ID; Divine UC; Adeyemi R; Ayinde KS; Olaoba OT; Apu C; Du L; Lu Q; Yin X; Adelusi TI
    Pharmacol Res; 2021 May; 167():105577. PubMed ID: 33774182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.